IDIA.SW实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:30):

Stats
今日成交量	401 006
平均成交量	1.16M
市值	379.96M
EPS	CHF0 ( 2024-02-05 )
下一个收益日期	( CHF-0.810 ) 2024-05-20
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-0.950
ATR14	CHF0.0100 (0.50%)

音量相关性

長: -0.01 (neutral)

短: -0.14 (neutral)

Signal:(49.639) Neutral

Idorsia Ltd 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Idorsia Ltd 相关性 - 货币/商品

-0.45
( neutral )

0.23
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.46
( neutral )

Idorsia Ltd 财务报表

Annual	2023
营收:	CHF0
毛利润:	CHF0 (0.00 %)
EPS:	CHF0

FY	2023
营收:	CHF0
毛利润:	CHF0 (0.00 %)
EPS:	CHF0

FY	2022
营收:	CHF97.10M
毛利润:	CHF90.84M (93.55 %)
EPS:	CHF-4.67

FY	2021
营收:	CHF35.35M
毛利润:	CHF0.00 (0.00 %)
EPS:	CHF-3.77

Financial Reports:

No articles found.

Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.